Arginine-derived research compound · Fact sheet
Agmatine
Also known as Agmatine sulfate
Agmatine is an arginine-derived compound with early pain research. One short radiculopathy trial reported symptom improvement, but substantial differences between randomized and analyzed counts limit confidence and do not establish broad pain or mood benefits.
What is Agmatine?
Agmatine is formed by removal of carbon dioxide from arginine. It is not a peptide.
The human study used agmatine sulfate; free agmatine and multi-ingredient products are different exposures.
Benefits & claims
Interest in Agmatine spans cognition and sleep, recovery. Study findings apply to the named formulation and population.
What the evidence supports
- The short trial reported larger improvements in pain and quality-of-life measures with agmatine than placebo.
- Both groups improved, and the reduced analyzed sample raises attrition concerns.
- Animal neuroprotection or pain effects cannot establish antidepressant, cognitive or generalized analgesic benefit.
Research areas
- Formulation-specific human outcomes
- Mechanistic research
Dosage & frequency
Human study contextThis is an exposure from a named human study, not a generally established treatment or enhancement regimen.
Agmatine sulfate randomized radiculopathy study
Adults with herniated lumbar-disc-associated radiculopathy; 99 randomized, 61 analyzed
- Amount
- 2.670 g total daily agmatine sulfate
- Frequency
- Daily for 14 days
- Route studied or labeled
- Oral
This is the randomized phase, separate from earlier escalating cohorts. The indexed report states a daily total rather than a verified universal division schedule. Attrition limits inference.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- Agmatine is formed by removal of carbon dioxide from arginine. It is not a peptide.
Formulation differences
- The human study used agmatine sulfate; free agmatine and multi-ingredient products are different exposures.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Reproducibility in larger independent trials
- Long-term outcomes and adverse effects
- Equivalence of different preparations and interaction profiles
Side effects & risks
- The highest dose-escalation cohort included diarrhea and nausea.
- Short treatment and incomplete analysis cannot establish long-term safety or compatibility with multiple psychoactive medicines.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Early human evidenceThe randomized study enrolled 99 participants but analyzed 61. Earlier dose-escalation work and animal studies supply limited supporting context.
Studies
Dose escalation followed by randomized lumbar radiculopathy study.
Preclinical inflammatory, neuropathic and spinal-injury pain experiments.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
No FDA-approved Agmatine drug indication is established for the supplement uses discussed here. Supplement availability is not FDA approval of efficacy or safety.
No FDA-approved product for this entry
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
- Safety and Efficacy of Dietary Agmatine Sulfate in Lumbar Disc-associated Radiculopathy. An Open-label, Dose-escalating Study Followed by a Randomized, Double-blind, Placebo-controlled Trial.
- Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury.
- FDA: what approval means for supplements
Open questions
- Reproducibility in larger independent trials
- Long-term outcomes and adverse effects
- Equivalence of different preparations and interaction profiles
Summary
Animal neuroprotection or pain effects cannot establish antidepressant, cognitive or generalized analgesic benefit.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedSafety and Efficacy of Dietary Agmatine Sulfate in Lumbar Disc-associated Radiculopathy. An Open-label, Dose-escalating Study Followed by a Randomized, Double-blind, Placebo-controlled Trial.
Dose escalation followed by randomized lumbar radiculopathy study.
- pubmedAgmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury.
Preclinical inflammatory, neuropathic and spinal-injury pain experiments.
- fdaFDA: what approval means for supplements
Dietary supplements are not approved by FDA for safety and effectiveness before marketing.